Join +750K new investors every month who copy stock picks from billionaire's portfoliosSign Up Free

LivaNova to shelve mitral heart valve device programme in restructuring

Published 20/11/2019, 14:38
© Reuters.  LivaNova to shelve mitral heart valve device programme in restructuring
MDT
-
LIVN
-

(Reuters) - LivaNova Plc (O:LIVN) said on Wednesday it would stop developing its minimally-invasive mitral heart valve device and restructure its heart valve unit after years of declining sales.

The company is racing with firms such as Medtronic Plc (N:MDT) to launch the first transcatheter mitral valve replacement (TMVR) device that can help patients avoid traditional open-heart surgeries through the use of a catheter or tube to replace the valve.

The soonest a replacement programme will hit the market is at least five years, Jefferies analyst Raj Denhoy said in a client note.

"Faced with that reality, a crowded landscape, and a $20 million annual development spend that likely increases over time— the decision to shutter the programme is not surprising."

The UK-based company said the restructuring of its heart valve business, which brought in nearly $130 million in 2018 sales or about 11% of total revenue, could impact about 150 employees in three of its plants and would also eliminate operational overlap.

LivaNova, which has about 4,000 employees, said the closure of its Minneapolis plant would be effective at the end of the year.

The company expects to record a non-cash impairment charge of about $135 million, the current book-value of its intangible TMVR assets, in the fourth quarter.

LivaNova said it would also incur employee severance costs in the fourth quarter and the first half of 2020.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.